Apnimed Inc. Company Profile
NASDAQ: APMDHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Oct 7, 4:00 PM ET · Delayed 15 min
Pre-market: 18.06 +0.11%
Apnimed at a glance
Apnimed Inc. (NASDAQ: APMD) is a Biotechnology: Pharmaceutical Preparations company in the Health Care sector headquartered in Cambridge, MA. Apnimed is led by Mr. Kevin Robert Lind and employs about 81 people. The company's shares have traded publicly since 2026.
At a market capitalization of $751.0 million, it is considered a small-cap company. Its SEC Central Index Key (CIK) is 0001745648, which identifies the company's filings on EDGAR.
Summary generated from market data by MetaCap's automated system. Methodology
What does Apnimed do?
Apnimed, Inc. operates as a clinical pharmaceutical company that develops and manufactures novel oral therapies that address the neurobiology of sleep-related breathing diseases in global markets. It offers AD109, an oral therapy designed to treat obstructive sleep apnea (OSA) by targeting the underlying neuromuscular dysfunction. The company was incorporated in 2017 and is headquartered in Cambridge, Massachusetts.
Business description based on the company's public filings.
Company information
- Legal name
- Apnimed Inc.
- Ticker
- NASDAQ: APMD
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- CEO
- Mr. Kevin Robert Lind
- Employees
- 81
- Headquarters
- 39 John F. Kennedy Street, Cambridge, MA, United States
- Phone
- 617 500 8880
- Website
- apnimed.com
- IPO year
- 2026
- Market cap
- $751.02M
- SEC CIK
- 0001745648
Companies similar to Apnimed
| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| VSTMVerastem Inc. | 8.27 | +6.65% | $748.51M | vs APMD |
| GYREGyre Therapeutics Inc. | 7.04 | -0.56% | $746.48M | vs APMD |
| ANNXAnnexon Inc. | 4.01 | -0.50% | $760.21M | vs APMD |
| HELPHelus Pharma Inc. | 10.51 | -2.32% | $767.86M | vs APMD |
| DSGNDesign Therapeutics Inc. | 11.69 | -2.34% | $731.58M | vs APMD |
| GERNGeron Corporation | 1.20 | -0.83% | $770.97M | vs APMD |
| AVTXAvalo Therapeutics Inc. | 13.58 | -0.07% | $728.30M | vs APMD |
| LXRXLexicon Pharmaceuticals Inc. | 1.76 | +0.57% | $783.12M | vs APMD |